OBJECTIVE: Studies on the prevalence of metabolic syndrome (MS) in European obese children using child-based criteria are scanty. Moreover, it is unknown if nontraditional cardiovascular disease (CVD) risk factors are associated with the MS at this early age in these subjects. DESIGN AND SUBJECTS: We studied the prevalence of the MS in 588 Caucasian obese children and adolescents by devising a World Health Organization derived definition and child-specific criteria, whose deviation from normalcy was based on an age, sex, and ethnically comparable control group of 1363 subjects. In a subgroup of 206 obese children, we investigated the association of the MS with nontraditional CVD risk factors. MEASUREMENTS: Fasting blood samples for glucose and lipids measurements were taken in both control and obese children. In addition, the obese children underwent an oral glucose tolerance test. In the subgroup of 206 obese children, albumin excretion rate , plasma uric acid, fibrinogen, plasminogen activator inhibitor type 1(PAI-1), C-reactive protein, interleukin 6 and white blood cells were also measured. RESULTS: The prevalence of MS was 23.3%. A similar prevalence of 23% of MS was recorded in the subgroup of 206 obese children in whom measurements of nontraditional CVD risk factors were available. After adjustment for the degree of obesity, subjects with MS had significantly higher uric acid (6.6+/-0.23 vs 6.1+/-0.12 mg/dl, P<0.0001) and PAI-1 plasma concentrations (231.4+/-25.50 vs 214.3+/-12.96 ng/ml, P<0.05) and a higher frequency of microalbuminuria (37 vs 20%, P<0.05) than those without MS. Microalbuminuria, uric acid and PAI-1 explained 10.6% of the variance of MS. CONCLUSION: Approximately, a quarter of Caucasian obese children have the MS. The association of MS with several nontraditional risk factors for CVD early in life suggests a heightened CVD risk in these individuals.
OBJECTIVE: Studies on the prevalence of metabolic syndrome (MS) in European obesechildren using child-based criteria are scanty. Moreover, it is unknown if nontraditional cardiovascular disease (CVD) risk factors are associated with the MS at this early age in these subjects. DESIGN AND SUBJECTS: We studied the prevalence of the MS in 588 Caucasian obesechildren and adolescents by devising a World Health Organization derived definition and child-specific criteria, whose deviation from normalcy was based on an age, sex, and ethnically comparable control group of 1363 subjects. In a subgroup of 206 obesechildren, we investigated the association of the MS with nontraditional CVD risk factors. MEASUREMENTS: Fasting blood samples for glucose and lipids measurements were taken in both control and obesechildren. In addition, the obesechildren underwent an oral glucose tolerance test. In the subgroup of 206 obesechildren, albumin excretion rate , plasma uric acid, fibrinogen, plasminogen activator inhibitor type 1(PAI-1), C-reactive protein, interleukin 6 and white blood cells were also measured. RESULTS: The prevalence of MS was 23.3%. A similar prevalence of 23% of MS was recorded in the subgroup of 206 obesechildren in whom measurements of nontraditional CVD risk factors were available. After adjustment for the degree of obesity, subjects with MS had significantly higher uric acid (6.6+/-0.23 vs 6.1+/-0.12 mg/dl, P<0.0001) and PAI-1 plasma concentrations (231.4+/-25.50 vs 214.3+/-12.96 ng/ml, P<0.05) and a higher frequency of microalbuminuria (37 vs 20%, P<0.05) than those without MS. Microalbuminuria, uric acid and PAI-1 explained 10.6% of the variance of MS. CONCLUSION: Approximately, a quarter of Caucasian obesechildren have the MS. The association of MS with several nontraditional risk factors for CVD early in life suggests a heightened CVD risk in these individuals.
Authors: Nicola L Hawley; Lauren M Wier; Haley L Cash; Satupaitea Viali; John Tuitele; Stephen T McGarvey Journal: Am J Hum Biol Date: 2012-03-20 Impact factor: 1.937
Authors: Gabriela Paredes-Turrubiarte; Antonio González-Chávez; Ruy Pérez-Tamayo; Beatriz Y Salazar-Vázquez; Vito S Hernández; Nayeli Garibay-Nieto; José Manuel Fragoso; Galileo Escobedo Journal: Clin Exp Med Date: 2015-04-18 Impact factor: 3.984
Authors: Trang H H D Nguyen; Hong K Tang; Patrick Kelly; Hidde P van der Ploeg; Michael J Dibley Journal: BMC Public Health Date: 2010-03-17 Impact factor: 3.295
Authors: Erin Rademacher; Michael Mauer; David R Jacobs; Blanche Chavers; Julia Steinke; Alan Sinaiko Journal: Clin J Am Soc Nephrol Date: 2008-04-09 Impact factor: 8.237
Authors: Nalini N E Radhakishun; Mariska van Vliet; Ines A von Rosenstiel; Jos H Beijnen; Michaela Diamant Journal: Pediatr Nephrol Date: 2013-03-19 Impact factor: 3.714